跳至主要内容
临床试验/NCT06905106
NCT06905106招募中不适用

POlycythemia, Proteins and ErYthropoiesis

Centre Hospitalier Universitaire Dijon1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2024年9月1日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
400
试验地点
1
主要终点
Measurement of various proteins involved in the regulation of erythropoiesis

研究概览

简要总结

Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Persons who have given their non-opposition
  • Patients with polycythemia:
  • haemoglobin value > 16 g/dl female or > 16.5 g/dl male
  • with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary [cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...)
  • Patients control:
  • persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of < 16 g/DL for women and < 16.5 g/DL for men

排除标准

  • Person subject to a measure of legal protection (guardianship, tutorship)
  • Person subject to a court order
  • Pregnant, parturient or nursing woman
  • Incapable of expressing consent

研究组 & 干预措施

Patients with polycythemia

Whatever the origin of polycythemia

干预措施: Collection of tube bottoms from blood samples taken in the clinic (Biological)

Patient controls

Patients with the same pathological features but without polycythemia

干预措施: Collection of tube bottoms from blood samples taken in the clinic (Biological)

结局指标

主要结局

Measurement of various proteins involved in the regulation of erythropoiesis

时间窗: at baseline

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验